1 Small Pharma Proving That Partnerships Payhttp://www.fool.com/investing/general/2012/12/12/1-small-pharma-proving-that-partnerships-pay.aspx Keith Speights
December 12, 2012
If drug companies could take personality tests, Isis Pharmaceuticals (NASDAQ: ISIS) would probably be classified as an extrovert. The company hasn't had any trouble making friends lately. Isis announced two significant partnership deals just this week.
Three in a row
The first two deals, announced earlier in 2012, targeted treatment of spinal muscular atrophy and myotonic dystrophy type 1. The latest collaboration relates to development of antisense drugs targeting three undisclosed neurological or neuromuscular disorders.
Under the terms of the most recent partnership agreement, Isis will develop drugs through the end of phase 2 trials. Biogen will have the option to license the drugs up until that point and carry out the remainder of the development and commercialization efforts.